IFN GAMMA GENE EXPRESSION IN HUMAN B-CELL LINES: INDUCTION BY IL-2, PKC ACTIVATORS AND POSSIBLE ROLE OF DEMETHYLATION AND DNA-BINDING PROTEIN IN GENE REGULATION (MEETING ABSTRACT)

Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

IFN GAMMA GENE EXPRESSION IN HUMAN B-CELL LINES: INDUCTION BY IL-2, PKC ACTIVATORS AND POSSIBLE ROLE OF DEMETHYLATION AND DNA-BINDING PROTEIN IN GENE REGULATION (MEETING ABSTRACT)

Proc Annu Meet Am Assoc Cancer Res; 33:A2374 1992. Unique Identifier : AIDSLINE ICDB/92684538
Pang Y; Norihisa Y; Benjamin D; Kantor R; Young HA; BCDP, PRI/Dyn Corp, NCI-FCRDC, Frederick, MD 21702

Abstract: Interferon-gamma (IFN gamma) is an immunoregulatory lymphokine which plays an important role in immune system maturation, development and function. In contrast to its broad spectrum of action, IFN gamma expression is usually linked to activated T cells and large granular lymphocytes. The possibility that other lymphocyte populations express this protein is of interest, especially since this would create an evaluation of lymphokine-signaling networks. In this study, we have analyzed the molecular and biochemical pathways involved in the production of IFN gamma by EBV-positive B-cell lines, one derived from a patient with Burkitt's lymphoma and the other from a patient with AIDS and Burkitt's lymphoma. The production of IFN gamma is either spontaneous or triggered by PKC activators and is enhanced by IL-2 through the IL-2-receptor beta chain. IFN gamma genomic DNA analysis indicates that demethylation of the DNA in the promoter region of the gene may play a role in the activation of IFN gamma gene expression in the B-cell lines. Furthermore, in vivo footprinting analysis of the promoter region reveals distinct differences in protein binding between producer and nonproducer cell lines. These in vitro data indicate that it now may be important to consider malignant B cells as a potential, albeit rare, source of IFN gamma in vivo.

Keywords: Acquired Immunodeficiency Syndrome/METABOLISM B-Lymphocytes/*DRUG EFFECTS/ENZYMOLOGY/METABOLISM Burkitt's Lymphoma/METABOLISM Cell Line DNA/GENETICS DNA-Binding Proteins/METABOLISM Enzyme Activation Gene Expression/*DRUG EFFECTS Human Interferon Type II/*GENETICS Methylation Promoter Regions (Genetics) Protein Kinase C/*METABOLISM ABSTRACT
921030
M92A1035

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .